TABLE 1.
Patient, tumor, and treatment characteristics (n = 85)
| Characteristic | No. or median (range) |
|---|---|
| Sex | |
| Male | 80 |
| Female | 5 |
| Age (y) | 67 (46–82) |
| Performance status | |
| 1 | 31 |
| 2 | 54 |
| Smoking status | |
| Never | 15 |
| Current or former smoker | 70 |
| Treatment pattern | |
| cCRT | 17 |
| sCRT | 26 |
| RT alone | 42 |
| Honeycombing score on CT | |
| 0 | 34 |
| 1 | 20 |
| 2 | 23 |
| 3 | 8 |
| Platinum‐based chemotherapy | |
| Paclitaxel | 21 |
| Pemetrexed | 6 |
| Etoposide | 10 |
| Gemcitabine | 6 |
| mGAP score (n = 73) | |
| 1 | 8 |
| 2 | 16 |
| 3 | 21 |
| 4 | 23 |
| 5 | 5 |
| Clinical stage | |
| IIIA | 33 |
| IIIB | 52 |
| Tumor location | |
| Lower lobe | 31 |
| Non‐lower lobe | 54 |
| Histology | |
| Squamous | 54 |
| Non‐squamous | 31 |
| %FVC (n = 73) | 68.6 (41.00–125.30) |
| MLD (Gy) (n = 83) | 13.71 (2.30–20.69) |
| V5% (n = 83) | 52.74 (16.61–86.54) |
| V20% (n = 83) | 23.00 (8.77–30.39) |
| Radiation dose (Gy) | 60.00 (40.00–70.00) |
Abbreviations: cCRT, concurrent chemoradiotherapy; CRT, chemoradiotherapy; RT, radiotherapy; mGAP, modified age gender, and pulmonary physiology index; FVC, forced vital capacity; MLD, mean lung dose; V5, the percentage of lung volume minus gross tumor volume receiving >5 Gy; V20, the percentage of lung volume minus gross tumor volume receiving >20 Gy.